---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-112341"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2025-09-02T23:59:59+00:00"
generated_at: "2026-05-17T09:07:57.341530+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# FibroGen completes $220M sale of China ops to AstraZeneca; cash runway extended to 2028

## Summary
- Total consideration ~$220M ($85M enterprise value + ~$135M net cash), $60M above initial guidance.
- Repaid ~$81M term loan to Morgan Stanley Tactical Value; cash runway now extended into 2028.
- Phase 2 monotherapy trial of FG-3246 in mCRPC on track to commence in Q3 2025.
- Phase 3 protocol for roxadustat in LR-MDS anemia to be submitted in Q4 2025 after positive FDA meeting.
- FibroGen retains roxadustat rights in U.S. and all markets not licensed to Astellas (excl. China/South Korea).

## SEC filing metadata
- accession: 0000950170-25-112341
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2025-09-02T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000095017025112341/0000950170-25-112341-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000095017025112341/fgen-20250829.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-112341
- JSON: https://secwatch.observer/filing/0000950170-25-112341.json
- Plain text: https://secwatch.observer/filing/0000950170-25-112341.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.